Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

被引：0
|
作者：
Linda A. Gallo
Micheal S. Ward
Amelia K. Fotheringham
Aowen Zhuang
Danielle J. Borg
Nicole B. Flemming
Ben M. Harvie
Toni L. Kinneally
Shang-Ming Yeh
Domenica A. McCarthy
Hermann Koepsell
Volker Vallon
Carol Pollock
Usha Panchapakesan
Josephine M. Forbes
机构：
来源：
Scientific Reports | / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Scientific Reports 6: Article number: 26428; published online: 26 May 2016; updated: 07 July 2016 This Article contains errors in the Acknowledgements section. “The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926).” should read: “The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia.
引用
收藏
相关论文
共 28 条
  • [1] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
    Gallo, Linda A.
    Ward, Micheal S.
    Fotheringham, Amelia K.
    Zhuang, Aowen
    Borg, Danielle J.
    Flemming, Nicole B.
    Harvie, Ben M.
    Kinneally, Toni L.
    Yeh, Shang-Ming
    McCarthy, Domenica A.
    Koepsell, Hermann
    Vallon, Volker
    Pollock, Carol
    Panchapakesan, Usha
    Forbes, Josephine M.
    SCIENTIFIC REPORTS, 2016, 6
  • [2] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
    Linda A. Gallo
    Micheal S. Ward
    Amelia K. Fotheringham
    Aowen Zhuang
    Danielle J. Borg
    Nicole B. Flemming
    Ben M. Harvie
    Toni L. Kinneally
    Shang-Ming Yeh
    Domenica A. McCarthy
    Hermann Koepsell
    Volker Vallon
    Carol Pollock
    Usha Panchapakesan
    Josephine M. Forbes
    Scientific Reports, 6
  • [3] The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice
    Gallo, Linda A.
    Ward, Micheal S.
    Fotheringham, Amelia K.
    Zhuang, Aowen
    Koepsell, Hermann
    Vallon', Volker
    Pollock, Carol
    Panchapakesan, Usha
    Forbes, Josephine M.
    FASEB JOURNAL, 2016, 30
  • [4] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice (vol 6, 26428, 2016)
    Gallo, Linda A.
    Ward, Micheal S.
    Fotheringham, Amelia K.
    Zhuang, Aowen
    Borg, Danielle J.
    Flemming, Nicole B.
    Harvie, Ben M.
    Kinneally, Toni L.
    Yeh, Shang-Ming
    McCarthy, Domenica A.
    Koepsell, Hermann
    Vallon, Volker
    Pollock, Carol
    Panchapakesan, Usha
    Forbes, Josephine M.
    SCIENTIFIC REPORTS, 2016, 6
  • [5] Sodium Glucose Transporter Type 2 (SGLT2) Inhibitor, Empagliflozin, Improves Diastolic Function in Female Diabetic db/db Mice
    Demarco, Vincent G.
    Aroor, Annayya R.
    Nistala, Ravi
    Garro, Mona
    Mayoux, Eric W.
    Whaley-Connell, Adam
    Sowers, James R.
    DIABETES, 2015, 64 : A552 - A552
  • [6] The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
    Kern, Matthias
    Kloeting, Nora
    Mark, Michael
    Mayoux, Eric
    Klein, Thomas
    Blueher, Matthias
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (02): : 114 - 123
  • [7] SGLT2 Inhibitor Therapy Improves Blood Glucose but Does Not Prevent Albuminuria nor Glomerular Hypertrophy in Diabetic db/db Mice
    Takiyama, Yumi
    Sera, Toshihiro
    Nakamura, Masanori
    Yanagimachi, Tsuyoshi
    Bessho, Ryoichi
    Fujita, Yukihiro
    Hoshino, Masato
    Uesugi, Kentaro
    Saijo, Yasuaki
    Yagi, Naoto
    Haneda, Masakazu
    DIABETES, 2017, 66 : A134 - A134
  • [8] Treatment of Hyperglycemia with the SGLT2 Inhibitor Empagliflozin Ameliorates Markers of Islet Endothelial Dysfunction in C57BL/KsJ.db/db Diabetic Mice
    Hull, Rebecca L.
    Hogan, Meghan F.
    DIABETES, 2017, 66 : A568 - A568
  • [9] Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin
    Norgaard, Sisse Andersen
    Briand, Francois
    Sand, Fredrik Wolfhagen
    Galsgaard, Elisabeth Douglas
    Sondergaard, Henrik
    Sorensen, Dorte Bratbo
    Sulpice, Thierry
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 860
  • [10] Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice
    Okauchi, Seizo
    Shimoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 470 (03) : 772 - 782
123